Olema Pharmaceuticals Grants Stock Options to New Employees
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2026
0mins
Should l Buy OLMA?
Source: Newsfilter
Olema Pharmaceuticals' stock fell 20.23% and hit a 20-day low amid broader market declines.
The company granted stock options for a total of 205,000 shares to four new employees, a move approved by the Compensation Committee to enhance competitiveness. The options have an exercise price of $24.02 per share and vest over four years, aligning employee incentives with company performance. Additionally, Olema is advancing its lead candidate palazestrant through Phase 3 trials, showcasing its innovative potential in targeted therapies for breast cancer.
This stock option grant reflects Olema's commitment to attracting talent, but the significant drop in stock price indicates investor concerns, particularly in the context of a bearish market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OLMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OLMA
Wall Street analysts forecast OLMA stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.760
Low
20.00
Averages
42.00
High
60.00
Current: 15.760
Low
20.00
Averages
42.00
High
60.00
About OLMA
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Olema Pharmaceuticals and Capital One See High Options Trading Volume
- Olema Options Volume: Olema Pharmaceuticals Inc saw options trading volume of 6,864 contracts, equating to approximately 686,400 shares, which represents about 55.1% of its average daily trading volume of 1.2 million shares over the past month, indicating heightened market interest in its future performance.
- High Put Option Activity: Notably, the $14 strike put option expiring on April 17, 2026, has seen 2,044 contracts traded today, representing around 204,400 underlying shares, suggesting increased investor expectations for a price decline.
- Capital One Options Trading: Capital One Financial Corp experienced options trading volume of 27,954 contracts, translating to approximately 2.8 million shares, or about 51.7% of its average daily trading volume of 5.4 million shares over the past month, reflecting market attention on its stock volatility.
- Active Put Option Trading: Particularly, the $220 strike put option expiring on March 20, 2026, has recorded 4,806 contracts traded today, representing about 480,600 underlying shares, indicating a cautious outlook from investors regarding Capital One's future performance.
See More
DJS Law Group Investigates Olema Pharmaceuticals Investor Claims
- Investigation Background: DJS Law Group has announced an investigation into claims on behalf of investors of Olema Pharmaceuticals (NASDAQ:OLMA), focusing on potential violations of securities laws, including misleading statements or failure to disclose critical information.
- Market Reaction: Following a report from Investor's Business Daily on March 9, 2026, regarding the failure of a Roche trial for an oral breast cancer medication, Olema's shares fell by over 19.6% in morning trading, indicating significant investor concern.
- Analyst Insights: Analyst Matthew Biegler highlighted that the Roche trial results negatively impact the thesis that oral SERDs can succeed in front-line breast cancer treatment, raising further doubts about Olema's competitive position in the market.
- Legal Service Commitment: DJS Law Group is dedicated to enhancing investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions and corporate governance litigation, aiming to provide high-value legal services to its clients.
See More
Oil Price Surge Drives Significant Stock Movements
- Oil Price Impact: Oil prices surged past $110 per barrel due to the ongoing Iran conflict, leading Chevron to hit an all-time high, while Talos Energy rose by 5%, and ConocoPhillips and Northern Oil gained 2% and 3% respectively, indicating strong performance among oil companies in a high-price environment.
- Hims & Hers Health Surge: The company's stock soared 39% after striking a deal with Novo Nordisk to sell its weight-loss drug, resolving a lawsuit over a copycat version, which is expected to significantly enhance its market share and brand reputation.
- Live Nation Settlement Near: Live Nation's shares rose 6% as it nears a settlement with the Department of Justice regarding monopoly allegations in the live concert industry, which, if successful, will stabilize and expand its future business operations.
- United Therapeutics Buyback Plan: The pharmaceutical company's shares increased by over 8% after its board authorized a $2 billion stock repurchase plan, with $1.5 billion allocated for accelerated buybacks, which is expected to boost investor confidence and enhance shareholder value.
See More
Olema Pharmaceuticals Shares Enter Oversold Territory
- Oversold Signal: Olema Pharmaceuticals (Ticker: OLMA) saw its RSI drop to 23.4 on Monday, indicating an oversold condition that suggests recent heavy selling may be exhausting, thus providing potential buying opportunities for investors.
- Price Fluctuation: OLMA shares hit a low of $12.99, and with a current trading price of $17.49 compared to its 52-week low of $2.86 and high of $36.2591, there is potential for a rebound that may attract bargain hunters.
- Market Comparison: OLMA's low RSI compared to the S&P 500 ETF's (SPY) current RSI of 36.7 may draw bullish investors' attention, suggesting that there is room for price recovery, which could influence overall market sentiment.
- Investor Strategy: In an oversold condition, investors might consider buying during price recoveries to capitalize on market volatility, especially in the current environment where finding undervalued stocks is becoming a strategy.
See More
Olema Pharmaceuticals Stock Declines Following Clinical Trial Setback
- Clinical Trial Setback: Olema Pharmaceuticals' phase 3 study of giredestrant combined with palbociclib failed to achieve a statistically significant improvement in progression-free survival compared to letrozole plus palbociclib, resulting in bearish pressure on the stock as investors express concerns over product prospects.
- Price Trend Analysis: Currently trading at $17.14, Olema's stock is 26.2% below its 20-day simple moving average and 19% below its 100-day SMA, indicating a bearish trend in the short to medium term, prompting investors to monitor shifts in market sentiment.
- Long-term Performance vs. Current Positioning: Despite a remarkable 294.05% increase in share price over the past 12 months, the stock is now closer to its 52-week lows, suggesting a weakening market confidence in future growth and potential risks of a pullback.
- Analyst Ratings and Price Targets: Despite facing short-term pressures, Olema's stock retains a Buy rating with an average price target of $37.33, reflecting analysts' confidence in its long-term potential, especially as several firms have recently raised their price targets.
See More
U.S. Stocks Drop Over 1% in Morning Trading
- Dow Jones Decline: The Dow Jones index fell by 1.30% to 46,883.33 points after market opening on Monday, reflecting investor concerns about economic outlook, which may lead to decreased confidence in the market.
- NASDAQ and S&P 500 Drop: The NASDAQ index decreased by 1.02% to 22,159.20 points, while the S&P 500 also fell by 1.14% to 6,663.14 points, indicating widespread weakness in the technology and consumer sectors.
- Energy Stocks Rise Slightly: Despite the overall market decline, energy stocks rose by 0.1%, suggesting that the energy sector remains resilient amid high oil prices, potentially attracting investor interest.
- Poor International Market Performance: European and Asia-Pacific markets also experienced declines, particularly Japan's Nikkei 225, which dropped by 5.20%, indicating that global economic uncertainties may negatively impact market sentiment.
See More
Olema Pharmaceuticals and Capital One See High Options Trading Volume
- Olema Options Volume: Olema Pharmaceuticals Inc saw options trading volume of 6,864 contracts, equating to approximately 686,400 shares, which represents about 55.1% of its average daily trading volume of 1.2 million shares over the past month, indicating heightened market interest in its future performance.
- High Put Option Activity: Notably, the $14 strike put option expiring on April 17, 2026, has seen 2,044 contracts traded today, representing around 204,400 underlying shares, suggesting increased investor expectations for a price decline.
- Capital One Options Trading: Capital One Financial Corp experienced options trading volume of 27,954 contracts, translating to approximately 2.8 million shares, or about 51.7% of its average daily trading volume of 5.4 million shares over the past month, reflecting market attention on its stock volatility.
- Active Put Option Trading: Particularly, the $220 strike put option expiring on March 20, 2026, has recorded 4,806 contracts traded today, representing about 480,600 underlying shares, indicating a cautious outlook from investors regarding Capital One's future performance.
See More
DJS Law Group Investigates Olema Pharmaceuticals Investor Claims
- Investigation Background: DJS Law Group has announced an investigation into claims on behalf of investors of Olema Pharmaceuticals (NASDAQ:OLMA), focusing on potential violations of securities laws, including misleading statements or failure to disclose critical information.
- Market Reaction: Following a report from Investor's Business Daily on March 9, 2026, regarding the failure of a Roche trial for an oral breast cancer medication, Olema's shares fell by over 19.6% in morning trading, indicating significant investor concern.
- Analyst Insights: Analyst Matthew Biegler highlighted that the Roche trial results negatively impact the thesis that oral SERDs can succeed in front-line breast cancer treatment, raising further doubts about Olema's competitive position in the market.
- Legal Service Commitment: DJS Law Group is dedicated to enhancing investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions and corporate governance litigation, aiming to provide high-value legal services to its clients.
See More
Oil Price Surge Drives Significant Stock Movements
- Oil Price Impact: Oil prices surged past $110 per barrel due to the ongoing Iran conflict, leading Chevron to hit an all-time high, while Talos Energy rose by 5%, and ConocoPhillips and Northern Oil gained 2% and 3% respectively, indicating strong performance among oil companies in a high-price environment.
- Hims & Hers Health Surge: The company's stock soared 39% after striking a deal with Novo Nordisk to sell its weight-loss drug, resolving a lawsuit over a copycat version, which is expected to significantly enhance its market share and brand reputation.
- Live Nation Settlement Near: Live Nation's shares rose 6% as it nears a settlement with the Department of Justice regarding monopoly allegations in the live concert industry, which, if successful, will stabilize and expand its future business operations.
- United Therapeutics Buyback Plan: The pharmaceutical company's shares increased by over 8% after its board authorized a $2 billion stock repurchase plan, with $1.5 billion allocated for accelerated buybacks, which is expected to boost investor confidence and enhance shareholder value.
See More
Olema Pharmaceuticals Shares Enter Oversold Territory
- Oversold Signal: Olema Pharmaceuticals (Ticker: OLMA) saw its RSI drop to 23.4 on Monday, indicating an oversold condition that suggests recent heavy selling may be exhausting, thus providing potential buying opportunities for investors.
- Price Fluctuation: OLMA shares hit a low of $12.99, and with a current trading price of $17.49 compared to its 52-week low of $2.86 and high of $36.2591, there is potential for a rebound that may attract bargain hunters.
- Market Comparison: OLMA's low RSI compared to the S&P 500 ETF's (SPY) current RSI of 36.7 may draw bullish investors' attention, suggesting that there is room for price recovery, which could influence overall market sentiment.
- Investor Strategy: In an oversold condition, investors might consider buying during price recoveries to capitalize on market volatility, especially in the current environment where finding undervalued stocks is becoming a strategy.
See More
Olema Pharmaceuticals Stock Declines Following Clinical Trial Setback
- Clinical Trial Setback: Olema Pharmaceuticals' phase 3 study of giredestrant combined with palbociclib failed to achieve a statistically significant improvement in progression-free survival compared to letrozole plus palbociclib, resulting in bearish pressure on the stock as investors express concerns over product prospects.
- Price Trend Analysis: Currently trading at $17.14, Olema's stock is 26.2% below its 20-day simple moving average and 19% below its 100-day SMA, indicating a bearish trend in the short to medium term, prompting investors to monitor shifts in market sentiment.
- Long-term Performance vs. Current Positioning: Despite a remarkable 294.05% increase in share price over the past 12 months, the stock is now closer to its 52-week lows, suggesting a weakening market confidence in future growth and potential risks of a pullback.
- Analyst Ratings and Price Targets: Despite facing short-term pressures, Olema's stock retains a Buy rating with an average price target of $37.33, reflecting analysts' confidence in its long-term potential, especially as several firms have recently raised their price targets.
See More
U.S. Stocks Drop Over 1% in Morning Trading
- Dow Jones Decline: The Dow Jones index fell by 1.30% to 46,883.33 points after market opening on Monday, reflecting investor concerns about economic outlook, which may lead to decreased confidence in the market.
- NASDAQ and S&P 500 Drop: The NASDAQ index decreased by 1.02% to 22,159.20 points, while the S&P 500 also fell by 1.14% to 6,663.14 points, indicating widespread weakness in the technology and consumer sectors.
- Energy Stocks Rise Slightly: Despite the overall market decline, energy stocks rose by 0.1%, suggesting that the energy sector remains resilient amid high oil prices, potentially attracting investor interest.
- Poor International Market Performance: European and Asia-Pacific markets also experienced declines, particularly Japan's Nikkei 225, which dropped by 5.20%, indicating that global economic uncertainties may negatively impact market sentiment.
See More
